Also see: Citi, Peabody: Analysts' New Ratings
Editor's Note: Green and red arrows refer to intraday stock price movement.
NEW YORK (TheStreet) -- STOCK COMMENTS / EPS CHANGES
Arch Capital (ACGL) estimates were cut through 2011 at UBS. Reflects an increase of the second-quarter 2011 catastrophe loss estimate, UBS said. Maintain Neutral rating and $34 price target.Cliffs Natural Resources (CLF) estimates were increased through 2013 at UBS. Company announces phase III development of Bloom Lake, UBS said. Maintain Neutral rating and $34 price dtarget. Campbell Soup (CPB) estimates, target were raised at Goldman Sachs. Shares now seen reaching $34, and estimates were also increased, as a restructuring program was announced, Goldman said. Neutral rating. Goldman Sachs (GS) numbers were lowered through 2013 at Credit Suisse. Company is facing difficult market conditions, Credit Suisse said. Outperform rating and new $170 price target. Harsco (HSC) price target was cut at Jefferies to $38. Infrastructure business is still a work in progress, Jefferies said. Buy rating. Maidenform (MFB) estimates, target were lowered at Citigroup. Shares now seen reaching $38. Estimates were also lowered, as sales have not been as robust as expected, Citigroup said. Buy rating. Morgan Stanley (MS) numbers were reduced at Credit Suisse. Shares now seen reaching $33. Estimates also cut, given tougher market conditions, Credit Suisse said. Outperform rating. Nike (NKE) estimates, target raised at Citigroup. Shares now seen reaching $98, according to Citigroup. Estimates also increased on renewed apparel growth and innovation in footwear. Buy rating. Progress Energy (PGN) target cut at Jefferies. Shares of PGN now seen reaching $48.50, according to Jefferies. Company could face delays at Crystal River, Jefferies said. Hold rating. Rowan (RDC) estimates were cut through 2012 at UBS. Reflects closing of LTI sale and fleet status update. Maintain Buy rating and $50 price target. Sigma Designs (SIGM) estimates, target were reduced at UBS. Shares now seen reaching $8.50. Estimates also lowered on IPTV segment recovery and sales mix uncertainties, UBS said. Maintain Neutral rating. SYNNEX (SNX) estimates, target cut at Goldman Sachs. Shares now seen reaching $33. Estimates also lowered citing Japan weakness, Goldman said. Neutral rating. Watson Pharmaceuticals (WPI) estimates, target raised at Morgan Stanley. Shares now seen reaching $78, according to Morgan Stanley. Estimates also increased on lower-than-expected royalties on Concerta and Specifar accretion, Morgan Stanley added. Overweight rating. End of report.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV